ECONOMIC FEASIBILITY OF NEW CHEMOTHERAPY REGIMENS FOR TREATMENT OF TUBERCULOSIS PATIENTS WITH EXTENSIVE DRUG RESISTANCE

The article presents economic feasibility evaluation for using high-priced drugs in the regimens for treatment of tuberculosis patients with extensive drug resistance.

Subjects and Methods. Treatment efficiency was evaluated in 175 tuberculosis patients with extensive drug resistance, treated by four different regimens, including third line drugs and without them; the economic impact of each regimen was evaluated. Two types of pharmaco-economic analysis were used: costs – effectiveness and budget impact analysis.

Results of the study. Despite the significant costs of regimens containing moxifloxacin, linezolid, and bedaquiline, the co-efficient of costs – effectiveness turned out to be the lowest. When using models for comparing costs and losses over 5 year period of XDR TB patients treatment it was found out that regimens containing moxifloxacin, linezolid and bedaquiline possessed significant economic predominance which required major investment at the initial stages of introduction, and by the end providing savings from 46.3 to 65.3% of the budget compared to the regimens without these drugs. The obtained results provide the evidence that use of regimens containing new highly effective drugs (moxifloxacin, linezolid and bedaquiline) in rational combinations with basic and reserve drugs, prescribed with consideration of drug resistance profile allow achieving the significant economic effect. 

1. Vasilyeva I.А., Bagdasaryan T.R., Balasanyants G.S., Bogorodskaya E.M., Borisov S.E., Valiev R.Sh., Kazenny B.Ya., Kazimirova N.E., Krasnov V.А., Lovacheva O.V., Maliev B.M., Maryandyshev А.O., Morozova T.I., Samoylova А.G., Sevastyanova E.V., Skornyakov S.N., Smerdin S.V., Stakhanov V.А., Chernousova L.N., Ergeshov А.E. et al. Federalnye klinicheskiye rekomendatsii po diagnostike i lecheniyu tuberkuleza organov dykhaniya s mnozhestvennoy i shirokoy lekarstennoy ustoichivostyu vozbuditelya. [Federal clinical recommendations for diagnosis and treatment of respiratory tuberculosis with multiple and extensive drug resistance]. Russian Phthisiologists' Society 47 p.

2. Kasaeva T.Ch., Gabbasova L.А., Moskalev А.А. et al. Tuberkulez v Rossiyskoy Federatsii 2012, 2013, 2014 g. Аnaliticheskiy obzor statisticheskikh pokazateley, ispolzuemykh v Rossiyskoy Federatsii i v mire. [Tuberculosis in the Russian Federation in 2011, 2013. 2014. Analytic review of statistic rates used in the Russian Federation and in the world]. Moscow, Triada Publ., 2015, 311 p.

3. On Social Care for the Disables in the Russian Federation. Federal Law no. 181-FZ, approved by State Duma as of November 24, 1995 (Revision as of 19.12.2016). Moscow, Sobraniye Zakonodatelstva RF Publ., 2016, 24 p. (In Russ.)

4. On Work Pensions in the Russian Federation. Federal Law no. 173-FZ, approved by State Duma as of November 17, 2001 (Revision as of 10.03.2017). Moscow, Sobraniye Zakonodatelstva RF Publ., 2015, 54 p. (In Russ.)

5. Edict no. 951 by RF MoH as of 29.19.2014 On Approval of Guidelines for Improvement of Respiratory Tuberculosis Diagnostics and Treatment. Moscow, 2014, 47 p. (In Russ.)

6. Yagudina R.I., Kulikov А.Yu., Metelkin I.А. Methods of cost-effectiveness analysis in pharmacoeconomic research. Farmakoekonomika, 2012, vol. 5, no. 4, pp. 3-8. (In Russ.)

7. Yagudina R.I., Serpik V.G., Ugrekhelidze D.T. Methodological basics of budget impact analysis. Farmakoekonomika: Teoriya i Praktika, 2015, vol. 3, no. 4, pp. 5-8. (In Russ.)

8. Akiakir Y. Correlates of treatment outcomes of multidrug-resistant tuberculosis (MDR-TB): a systematic review and meta-analysis. Montreal. MSc Thesis McGill University. 2010.

9. Caminero J., Sotgiu G., Zumla A. et al. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect. Dis., 2010, no. 10, pp. 621-629.

10. Cavalieri S.J., Biehle J.R., Sanders W.E.Jr. Synergistic activities of clarithromycin and antituberculous drugs against multidrug-resistant Mycobacterium tuberculosis. Antimicrob. Agents, Chemother., 1995, no. 39 (7), pp. 1542-1545.

11. Chambers H.F., Turner J., Schecter G.F. Imipenem for treatment of tuberculosis in mice and humans. Antimicrob. Agents Chemother., 2005, no. 49 (7), pp. 2816-2821.

12. Falzon D., Gandhi N., Migliori G.B., Sotgiu G., Cox H.S., Holtz T.H., Hollm-Delgado M.G., Keshavjee S., DeRiemer K., Centis R., D'Ambrosio L., Lange C.G., Bauer M., Menzies D. Collaborative group for meta-analysis of individual patient data in MDR-TB. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur. Respir. J., 2013, no. 42 (1), pp. 156-168.

13. Kamolratanakul P., Hiransithikul N., Singhadong N. Cost analysis of different types of tuberculosis patients at tuberculosis centers in Thailand Southeast Asian. J. Trop. Med. Public Health, 2002, no. 33, pp. 321-330.

14. Kim D.H., Kim H.J., Park S.K., Kong S.J., Kim Y.S., Kim T.H., Kim E.K., Lee K.M., Lee S.S., Park J.S., Koh W.J., Lee C.H., Shim T.S. Treatment outcomes and survival based on drug resistance patterns in multidrug-resistant tuberculosis. Am. J. Respir. Crit. Care Med., 2010, no. 182 (1), pp. 113-119.

15. Liu C.H., Li L., Chen Z., Wang Q., Hu Y.L., Zhu B., Woo P.C. Characteristics and treatment outcomes of patients with MDR and XDR tuberculosis in a TB referral hospital in Beijing: a 13-year experience. PLoS One, 2011, no. 6 (4), pp. e19399.

16. Menzies D., Oxlade O., Lewis M. Costs for tuberculosis care in Canada ‒ Ottawa: Public Health Agency of Canada, 2006.

17. Menzies R. Multidrug-resistant tuberculosis treatment regimens and patient outcomes: an Individual Patient Data (IPD) meta-analysis of 9153 patients. PLos Medicine, 2012.

18. Migliori G.B., Sotgiu G., Richardson D'Arcy M., Centis R., Facchini A., Guenther G., Spanevello A., Lange C. MDR-TB and XDR-TB: drug resistance and treatment outcomes. Eur. Respir. J., 2009, no. 34 (3), pp. 778-779.

19. Orenstein E.W., Basu S., Shah N.S., Andrews J.R. et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect. Dis., 2009, vol. 9, no. 3, pp. 153-161.